A Novel Nanoparticle Platelet Analogue for Radiation-Induced Thrombocytopenia

该合同将推进主要通过减轻和/或治疗辐射引起的血小板减少症来提高存活率的主要候选药物或生物制品的开发，进行转化性研究和开发，并提供支持提交研究新药(IND)申请和最终获得FDA批准或许可的更多信息和数据。该合同有一个明确的产品开发路径，用于领先的医疗对策，其中包括根据合同进行的IND-Enabling研究。

The contract will advance the development of lead candidate drugs or biological products that increase survival primarily by mitigating and/or treating radiation-induced thrombocytopenia, conduct translational research and development, and provide additional information and data that support submission of an Investigational New Drug (IND) application and eventual FDA approval or licensure. The contract has a well-defined product development path for a lead medical countermeasure that includes IND-enabling studies to be performed under the contract.